Michael F Bassetti
Overview
Explore the profile of Michael F Bassetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basree M, Witt J, Uboha N, Lubner M, Minter R, Weber S, et al.
Pract Radiat Oncol
. 2025 Feb;
PMID: 39924052
Background And Purpose: Elective nodal irradiation (ENI) in resectable pancreatic cancer remains undefined, though occult nodal disease is common. This study investigated the use of neoadjuvant stereotactic body radiation therapy...
2.
Uboha N, Basree M, Eickhoff J, Deming D, Matkowskyj K, Maloney J, et al.
J Surg Oncol
. 2025 Jan;
PMID: 39757733
Background And Objectives: Standard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative...
3.
Lee S, Yadav P, Li Y, Meudt J, Strang J, Hebel D, et al.
Data Brief
. 2024 Dec;
57:111159.
PMID: 39717135
Purpose: Integrated MRI and linear accelerator systems (MR-Linacs) provide superior soft tissue contrast, and the capability of adapting radiotherapy plans to changes in daily anatomy. In this dataset, serial MRIs...
4.
Sanford N, Narang A, Aguilera T, Bassetti M, Chuong M, Erickson B, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(4):918-929.
PMID: 39510320
Purpose: Dose-escalated radiation therapy is increasingly used in the treatment of pancreatic cancer; however, approaches to target delineation vary widely. We present the first North American cooperative group consensus contouring...
5.
DeZeeuw A, Bassetti M, Carchman E, Heise C, Hayden D, Lawson E, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272920
Background: Although squamous cell carcinoma of the anus (SCCA) is a relatively uncommon malignancy in the United States, it continues to increase in incidence. Treatment for locoregional disease includes mitomycin...
6.
Boldrini L, Chiloiro G, Cusumano D, Yadav P, Yu G, Romano A, et al.
Radiol Med
. 2024 Mar;
129(4):615-622.
PMID: 38512616
Purpose: The accurate prediction of treatment response in locally advanced rectal cancer (LARC) patients undergoing MRI-guided radiotherapy (MRIgRT) is essential for optimising treatment strategies. This multi-institutional study aimed to investigate...
7.
Baschnagel A, Flakus M, Wallat E, Wuschner A, Chappell R, Bayliss R, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
119(5):1393-1402.
PMID: 38387810
Purpose: To determine whether 4-dimensional computed tomography (4DCT) ventilation-based functional lung avoidance radiation therapy preserves pulmonary function compared with standard radiation therapy for non-small cell lung cancer (NSCLC). Methods And...
8.
Crosby J, Bassetti M, Hurst Jr N, Kruser T, Glide-Hurst C
Cureus
. 2024 Jan;
15(12):e50459.
PMID: 38222202
For MR-guided radiation therapy treatment planning, an MRI and CT of the intended treatment site are typically acquired. Patients' prior treatments or procedures can cause image artifacts in one or...
9.
Chuong M, Lee P, Low D, Kim J, Mittauer K, Bassetti M, et al.
Radiother Oncol
. 2023 Dec;
191():110064.
PMID: 38135187
Background And Purpose: Radiation dose escalation may improve local control (LC) and overall survival (OS) in select pancreatic ductal adenocarcinoma (PDAC) patients. We prospectively evaluated the safety and efficacy of...
10.
Bassetti M, Morris B, Sethakorn N, Lang J, Schehr J, Zhao S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Dec;
118(5):1481-1489.
PMID: 38072321
Purpose: Ablative local treatment of all radiographically detected metastatic sites in patients with oligometastatic non-small cell lung cancer (NSCLC) increases progression-free survival (PFS) and overall survival (OS). Prior studies demonstrated...